Publicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (18)

2021

  1. A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients

    Blood Cells, Molecules, and Diseases, Vol. 86

  2. Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)

    Scientific Reports

2019

  1. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    Scientific Reports, Vol. 9, Núm. 1

  2. Identification of 58 mutations (26 Novel) in 94 of 109 symptomatic Spanish probands with protein C deficiency

    Thrombosis and Haemostasis, Vol. 119, Núm. 9, pp. 1409-1418

  3. Management of adult patients with primary immune thrombocytopenia (itp) in clinical practice: A consensus approach of the Spanish itp expert group

    Advances in Hematology, Vol. 2019

2016

  1. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice

    European Journal of Haematology, Vol. 97, Núm. 3, pp. 297-302

2015

  1. Multivariable time-dependent analysis of the impact of azacitidine in patients with lower-risk myelodysplastic syndrome and unfavorable specific lower-risk score

    Leukemia Research, Vol. 39, Núm. 1, pp. 52-57

  2. Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia

    American Journal of Hematology, Vol. 90, Núm. 3, pp. E40-E43

  3. Use of eltrombopag after romiplostim in primary immune thrombocytopenia

    British Journal of Haematology, Vol. 169, Núm. 1, pp. 111-116

2014

  1. Venous leg ulcer in the context of chronic venous disease

    Phlebology, Vol. 29, Núm. 4, pp. 220-226

2013

  1. Characterization and prognostic implication of 17 chromosome abnormalities in myelodysplastic syndrome

    Leukemia Research, Vol. 37, Núm. 7, pp. 769-776

  2. Negative impact of deep venous thrombosis on chronic venous disease

    Thrombosis Research, Vol. 131, Núm. 4

  3. Quality of life in patients with chronic venous disease: Influence of the socio-demographical and clinical factors

    International Angiology, Vol. 32, Núm. 4, pp. 433-441

2012

  1. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome

    Cancer, Vol. 118, Núm. 1, pp. 127-133

  2. The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome

    Leukemia Research, Vol. 36, Núm. 3, pp. 287-292

2011

  1. Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

    Cancer, Vol. 117, Núm. 24, pp. 5529-5537

2009

  1. Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: A comparison of presenting clinical characteristics and response to treatment

    Annals of Hematology, Vol. 88, Núm. 10, pp. 973-978

2008

  1. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms

    Haematologica, Vol. 93, Núm. 5, pp. 729-734